JPWO2023133201A5 - - Google Patents
Info
- Publication number
- JPWO2023133201A5 JPWO2023133201A5 JP2024540912A JP2024540912A JPWO2023133201A5 JP WO2023133201 A5 JPWO2023133201 A5 JP WO2023133201A5 JP 2024540912 A JP2024540912 A JP 2024540912A JP 2024540912 A JP2024540912 A JP 2024540912A JP WO2023133201 A5 JPWO2023133201 A5 JP WO2023133201A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- cancer
- pharmaceutical composition
- pharmaceutically acceptable
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263296676P | 2022-01-05 | 2022-01-05 | |
| US63/296,676 | 2022-01-05 | ||
| PCT/US2023/010204 WO2023133201A1 (en) | 2022-01-05 | 2023-01-05 | Deuterium-enriched piperidinyl-methyl-purine amines and related compounds and their use in treating diseases and conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025504379A JP2025504379A (ja) | 2025-02-12 |
| JP2025504379A5 JP2025504379A5 (https=) | 2026-01-14 |
| JPWO2023133201A5 true JPWO2023133201A5 (https=) | 2026-01-14 |
Family
ID=87074217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024540912A Pending JP2025504379A (ja) | 2022-01-05 | 2023-01-05 | 重水素濃縮ピペリジニル－メチル－プリンアミン及び関連化合物、ならびに疾患及び状態の治療におけるそれらの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12492203B2 (https=) |
| EP (1) | EP4460502A4 (https=) |
| JP (1) | JP2025504379A (https=) |
| KR (1) | KR20240158230A (https=) |
| CN (1) | CN119032094A (https=) |
| AU (1) | AU2023205553A1 (https=) |
| CA (1) | CA3242612A1 (https=) |
| IL (1) | IL314062A (https=) |
| MX (1) | MX2024008450A (https=) |
| WO (1) | WO2023133201A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021026803A1 (en) | 2019-08-14 | 2021-02-18 | Novartis Ag | Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents |
| AU2023397773A1 (en) * | 2022-12-12 | 2025-06-26 | K36 Therapeutics, Inc. | Pharmaceutical compositions containing a piperidinyl-methyl-purine amine and their use in treating diseases and conditions |
| US20250171445A1 (en) * | 2023-11-17 | 2025-05-29 | K36 Therapeutics, Inc. | Deuterium-enriched piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions |
| CN117843641B (zh) * | 2023-12-28 | 2025-04-25 | 和径医药科技（上海）有限公司 | Nsd3抑制剂及其制备方法和应用 |
| WO2025259850A1 (en) * | 2024-06-12 | 2025-12-18 | K36 Therapeutics, Inc. | Pharmaceutical compositions containing a deuterium-enriched piperidinyl-methyl-purine amine and their use in treating diseases and conditions |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010044981A2 (en) | 2008-09-18 | 2010-04-22 | Auspex Pharmaceutical ,Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| EP2463289A1 (en) * | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
| WO2021026803A1 (en) | 2019-08-14 | 2021-02-18 | Novartis Ag | Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents |
| US20220380371A1 (en) | 2019-09-20 | 2022-12-01 | Novartis Ag | Mll1 inhibitors and anti-cancer agents |
| AR122159A1 (es) | 2020-05-28 | 2022-08-17 | Novartis Ag | Inhibidores de mll1 y agentes antineoplásicos |
| WO2023225154A1 (en) | 2022-05-18 | 2023-11-23 | K36 Therapeutics, Inc. | Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions |
| AU2023273656A1 (en) | 2022-05-18 | 2024-11-28 | K36 Therapeutics, Inc. | Piperidinyl-methyl-purine amine d-tartaric acid salts, crystalline forms, and their use in treating medical diseases and conditions |
| WO2023225150A1 (en) | 2022-05-18 | 2023-11-23 | K36 Therapeutics, Inc. | Piperidinyl-methyl-purine amine fumaric acid salts, crystalline forms, and their use in treating medical diseases and conditions |
| WO2023225144A1 (en) | 2022-05-18 | 2023-11-23 | K36 Therapeutics, Inc. | Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions |
| US20250361235A1 (en) | 2022-05-23 | 2025-11-27 | K36 Therapeutics, Inc. | Piperidinyl-methylpurine benzenes and related compounds and their use in treating diseases and conditions |
| US20250206740A1 (en) | 2022-05-23 | 2025-06-26 | K36 Therapeutics, Inc. | Piperidinyl-methylpurine pyrimidines and related compounds and their use in treating diseases and conditions |
| EP4583915A1 (en) | 2022-09-09 | 2025-07-16 | The Trustees Of Columbia University In The City Of New York | Methods of treating neuroendocrine prostate cancer (nepc) by inhibiting nuclear receptor binding set domain protein 2 (nsd2) |
| AU2023397773A1 (en) | 2022-12-12 | 2025-06-26 | K36 Therapeutics, Inc. | Pharmaceutical compositions containing a piperidinyl-methyl-purine amine and their use in treating diseases and conditions |
| US20250171445A1 (en) | 2023-11-17 | 2025-05-29 | K36 Therapeutics, Inc. | Deuterium-enriched piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions |
-
2023
- 2023-01-05 JP JP2024540912A patent/JP2025504379A/ja active Pending
- 2023-01-05 CA CA3242612A patent/CA3242612A1/en active Pending
- 2023-01-05 IL IL314062A patent/IL314062A/en unknown
- 2023-01-05 AU AU2023205553A patent/AU2023205553A1/en active Pending
- 2023-01-05 KR KR1020247026101A patent/KR20240158230A/ko active Pending
- 2023-01-05 WO PCT/US2023/010204 patent/WO2023133201A1/en not_active Ceased
- 2023-01-05 CN CN202380022643.3A patent/CN119032094A/zh active Pending
- 2023-01-05 EP EP23737585.2A patent/EP4460502A4/en active Pending
-
2024
- 2024-06-28 US US18/758,953 patent/US12492203B2/en active Active
- 2024-07-04 MX MX2024008450A patent/MX2024008450A/es unknown
-
2025
- 2025-10-24 US US19/368,828 patent/US20260049083A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7326622B2 (ja) | Ｅｒｋ阻害剤としてのスピロ系化合物およびその使用 | |
| RU2006122853A (ru) | Производные диарилмочевины для лечения заболеваний, зависимых от протеинкиназы | |
| JPWO2023214576A5 (https=) | ||
| JP7182304B2 (ja) | インドリノン化合物の使用 | |
| JPWO2019195124A5 (https=) | ||
| Tibes et al. | Phase I study of the novel Cdc2/CDK1 and AKT inhibitor terameprocol in patients with advanced leukemias | |
| HUP0401047A2 (hu) | Triazolo[4,5-d]pirimidin-származékok, alkalmazásuk purinergikus receptor-antagonistákként és a vegyületet tartalmazó gyógyszerkészítmények | |
| ATE361287T1 (de) | Neue indol-2-on derivate | |
| JPWO2013100014A1 (ja) | 抗腫瘍剤の効果増強剤 | |
| JP2003525244A (ja) | 抗腫瘍性アルキル化剤とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤 | |
| JP2014533264A (ja) | 三環式化合物、それらを含む組成物およびそれらの使用 | |
| JP2021530543A5 (https=) | ||
| MX2014002663A (es) | Nuevo esquema de administracion de la n-hidroxi-4-{2-[3-(n,n-dimet ilaminometil)benzofuran-2-ilcarbonilamino]etoxi}benzamida. | |
| JPWO2023133201A5 (https=) | ||
| AU2016246802A1 (en) | Boron-containing small molecules as antiprotozoal agents | |
| JP2021522246A5 (https=) | ||
| KR900001693A (ko) | 아자사이클릭 화합물, 이의 제조방법 및 이의 용도 | |
| JP2006517195A5 (https=) | ||
| KR920016418A (ko) | Nmda 길항제 | |
| JP2013523867A5 (https=) | ||
| RU2002105374A (ru) | Сочетанная терапия с использованием пентафторбензолсульфонамидов | |
| JP2006523664A5 (https=) | ||
| JP2009525987A (ja) | 黒色腫の治療のためのガリウム（ｉｉｉ）錯体の使用 | |
| JPWO1992004028A1 (ja) | 抗腫瘍効果増強剤及び抗腫瘍剤 | |
| JPWO2019195753A5 (https=) |